I believe @ecoool2 mentioned that he was ask to write a piece, but he decided not to clog up the process as they have people attending the meeting presenting their views which has more weight than written feedback, but what @The Yankee said is very valid too
I feel that in the end this is a scientific process and the data will stand up.
It wouldn't been able to go this far without solid data - so, I'm not overly concerned about these by-plays.
Maybe, the FDA should retrospectively take the approval back for Jafaki
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-260
-
- There are more pages in this discussion • 595 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.005(0.47%) |
Mkt cap ! $1.218B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.08 | $1.06 | $409.8K | 382.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 76145 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 3464 | 3 |
View Market Depth
| Last trade - 11.00am 03/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |